Novel polymorphisms associated with hyperalphalipoproteinemia and apparent cardioprotection.

[1]  S. Doggrell.  No cardiovascular benefit with evacetrapib – is this the end of the road for the ‘cetrapibs’? , 2017, Expert opinion on pharmacotherapy.

[2]  C. Granger,et al.  Evacetrapib and Cardiovascular Outcomes in High‐Risk Vascular Disease , 2017, The New England journal of medicine.

[3]  Andrew D. Johnson,et al.  Whole exome sequencing in the Framingham Heart Study identifies rare variation in HYAL2 that influences platelet aggregation , 2017, Thrombosis and Haemostasis.

[4]  E. Ikonen,et al.  A loss-of-function variant in OSBPL1A predisposes to low plasma HDL cholesterol levels and impaired cholesterol efflux capacity. , 2016, Atherosclerosis.

[5]  Dajiang J. Liu,et al.  Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease , 2016, Science.

[6]  David A Bluemke,et al.  Common genetic variants and subclinical atherosclerosis: The Multi-Ethnic Study of Atherosclerosis (MESA). , 2016, Atherosclerosis.

[7]  D. Rader,et al.  Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib. , 2015, Journal of the American College of Cardiology.

[8]  F. Tekola-Ayele,et al.  Gender-specific associations between ADIPOQ gene polymorphisms and adiponectin levels and obesity in the Jackson Heart Study cohort , 2015, BMC Medical Genetics.

[9]  R. Gibbs,et al.  Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies. , 2015, Human molecular genetics.

[10]  D. Stephan,et al.  Whole Exome Sequencing in Females with Autism Implicates Novel and Candidate Genes , 2015, International journal of molecular sciences.

[11]  C. Ballantyne.  Clinical Lipidology: A Companion to Braunwald's Heart Disease , 2014 .

[12]  Gen-Min Lin,et al.  Elevated concentrations of high-density lipoprotein cholesterol and cardiovascular risk paradox in patients with coronary heart disease and the equivalents. , 2014, International journal of cardiology.

[13]  S. Volpato,et al.  Flow-mediated dilation, carotid wall thickness and HDL function in subjects with hyperalphalipoproteinemia. , 2014, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[14]  J. Shendure,et al.  A general framework for estimating the relative pathogenicity of human genetic variants , 2014, Nature Genetics.

[15]  N. Barzilai,et al.  Phenotypes and genotypes of high density lipoprotein cholesterol in exceptional longevity. , 2013, Current vascular pharmacology.

[16]  D. Rader,et al.  Monogenic causes of elevated HDL cholesterol and implications for development of new therapeutics , 2013, Clinical lipidology.

[17]  R. D'Agostino,et al.  High-density lipoproteins: a consensus statement from the National Lipid Association. , 2013, Journal of clinical lipidology.

[18]  M. Stumvoll,et al.  An ACACB Variant Implicated in Diabetic Nephropathy Associates with Body Mass Index and Gene Expression in Obese Subjects , 2013, PloS one.

[19]  Markus Abt,et al.  Effects of dalcetrapib in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.

[20]  J. Ramírez,et al.  SNPs affecting serum metabolomic traits may regulate gene transcription and lipid accumulation in the liver. , 2012, Metabolism: clinical and experimental.

[21]  John Spertus,et al.  Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study , 2012, The Lancet.

[22]  Braxton D. Mitchell,et al.  Rare Variants in Ischemic Stroke: An Exome Pilot Study , 2012, PloS one.

[23]  Tanya M. Teslovich,et al.  Biological, Clinical, and Population Relevance of 95 Loci for Blood Lipids , 2010, Nature.

[24]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[25]  D. Noto,et al.  Novel mutations of CETP gene in Italian subjects with hyperalphalipoproteinemia. , 2009, Atherosclerosis.

[26]  J. O’Connell,et al.  A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection , 2008, Science.

[27]  M. Caulfield,et al.  Effects of torcetrapib in patients at high risk for coronary events. , 2007, The New England journal of medicine.

[28]  L. Kuller,et al.  Methods of assessing prevalent cardiovascular disease in the Cardiovascular Health Study. , 1995, Annals of epidemiology.

[29]  M. Miller,et al.  Long‐term Predictors of Subsequent Cardiovascular Events With Coronary Artery Disease and ‘Desirable’ Levels of Plasma Total Cholesterol , 1992, Circulation.

[30]  C. Glueck,et al.  Hyperalpha- and hypobeta-lipoproteinemia in octogenarian kindreds. , 1977, Atherosclerosis.

[31]  G. Miller,et al.  PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE , 1975, The Lancet.

[32]  W. PCastelli,et al.  HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study. , 1977 .